Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497427 | 0.88 | — | — | |
| SCHEMBL4269680 | 0.85 | TSHR (0.56) | TSHRCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL3086101 | 0.84 | ACE2 (0.38) | TSHRTDP1 | |
| SCHEMBL8373190 | 0.83 | TSHR (0.43) | TSHRCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1442459 | 0.83 | — | — | |
| SCHEMBL234630 | 0.82 | TSHR (0.39) | TSHR | |
| SCHEMBL31365425 | 0.82 | TSHR (0.53) | TSHRCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL29197507 | 0.82 | TSHR (0.53) | TSHRCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1441794 | 0.77 | — | — | |
| SCHEMBL599054 | 0.77 | TSHR (0.48) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854877-B1 | Process for the deacylation of cyclic lipopeptides | ASTELLAS PHARMA INC (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-2172546-A1 | Process for the deacylation of cyclic lipopeptides | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-0885957-B1 | PROCESS FOR THE DEACYLATION OF CYCLIC LIPOPEPTIDES | ASTELLAS PHARMA INC (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-1854877-A2 | Process for the deacylation of cyclic lipopeptides | Astellas Pharma Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| EP-1666587-A1 | Cyclic lipopeptide acylase | Astellas Pharma Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6884868-B1 | Cyclic hexapeptides having antibiotic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| EP-0941237-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999040108-A1 | NEW COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-12 | — | — | WO | disclosed |
| EP-0933422-A1 | CYCLIC LIPOPEPTIDE ACYLASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-04 | — | — | EP | disclosed |
| EP-0885957-A1 | PROCESS FOR THE DEACYLATION OF CYCLIC LIPOPEPTIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998052967-A1 | NEW ECHINOCANDIDE DERIVATIVES WITH ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
| WO-1998022498-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-28 | — | — | WO | disclosed |
| EP-0788511-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996011210-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | TSHR 3849/4885CHRM1 424/4885AKR1A1 601/4885 |
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | NGLY1, ARG1, ERG28 | TSHR 3903/4885CHRM1 431/4885AKR1A1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.